$1.69 Billion is the total value of Sofinnova Investments, Inc.'s 53 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| KRTX | Karuna Therapeutics Inc | $407,368,867 | -12.6% | 2,073,124 | 0.0% | 24.17% | -10.9% | |
| AVTE | Aerovate Therapeutics Inc | $110,129,500 | +76.7% | 3,758,686 | 0.0% | 6.54% | +80.2% | |
| VERA | Vera Therapeutics Inccl a | $61,560,903 | -9.2% | 3,181,442 | 0.0% | 3.65% | -7.4% | |
| YMAB | Y-mAbs Therapeutics Inc | $10,708,077 | -66.2% | 2,194,278 | 0.0% | 0.64% | -65.5% | |
| GRTX | Galera Therapeutics Inc | $4,594,731 | -14.4% | 3,083,712 | 0.0% | 0.27% | -12.5% | |
| INZY | Inozyme Pharma Inc | $3,838,073 | -60.8% | 3,655,308 | 0.0% | 0.23% | -60.0% | |
| NXTC | Nextcure Inc | $3,767,317 | -48.7% | 2,671,856 | 0.0% | 0.22% | -47.7% | |
| NCNA | Nucana PLCsponsored adr | $3,695,999 | -36.8% | 5,599,999 | 0.0% | 0.22% | -35.6% | |
| BOLT | Bolt Biotherapeutics Inc | $3,580,768 | -12.2% | 2,754,437 | 0.0% | 0.21% | -10.5% | |
| PDSB | PDS Biotechnology Corp | $1,882,782 | +344.1% | 142,635 | 0.0% | 0.11% | +348.0% | |
| Nucana PLC | $1,584,000 | -36.8% | 2,400,000 | 0.0% | 0.09% | -35.6% | ||
| OBSV | ObsEva SA | $688,695 | +2.0% | 4,749,623 | 0.0% | 0.04% | +5.1% | |
| SYBX | Synlogic Inc | $436,979 | -20.0% | 574,972 | 0.0% | 0.03% | -18.8% | |
| FUSN | Fusion Pharmaceuticals Inc | $368,862 | +4.8% | 117,099 | 0.0% | 0.02% | +10.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Natera, Inc. | 23 | Q3 2023 | 20.5% |
| Ascendis Pharma A/S | 23 | Q3 2023 | 27.9% |
| NuCana plc | 23 | Q3 2023 | 15.2% |
| Synlogic Inc. (fmrly Mirna) | 22 | Q2 2023 | 0.9% |
| Y-mAbs Therapeutics, Inc. | 21 | Q3 2023 | 6.5% |
| ObsEva SA | 20 | Q4 2022 | 11.0% |
| Nucana PLC | 19 | Q3 2023 | 9.7% |
| SYNDAX PHARMACEUTICALS INC | 19 | Q3 2023 | 2.2% |
| PDS Biotechnology Corporation | 19 | Q3 2023 | 0.1% |
| Karuna Therapeutics, Inc. | 18 | Q3 2023 | 27.1% |
View Sofinnova Investments, Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| OTONOMY, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Sofinnova Investments, Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Sofinnova Investments, Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.